MedTrace Logo

Plasma and Intrapulmonary Concentrations Study of WCK 5222

NCT03630094 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2018-08-14

No results posted yet for this study

Summary

This is a Phase 1, multiple dose, open-label pharmacokinetic study in healthy adult male and female subjects.

Conditions

  • PHA1A

Interventions

DRUG

FEP-ZID

A total of 7 doses of FEP-ZID via intravenous infusion over 60 min at q8hr dosing regimen

Sponsors & Collaborators

  • Wockhardt

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-03-31
Primary Completion
2017-06-30
Completion
2017-07-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03630094 on ClinicalTrials.gov